Valuation: Aligos Therapeutics, Inc.

Market Cap 3.56Cr 3.11Cr 2.87Cr 2.64Cr 4.99Cr 342.66Cr 5.1Cr 34Cr 13Cr 167.82Cr 13Cr 13Cr 577.72Cr P/E 2026 *
-0.82x
P/E 2027 * -1.35x
Enterprise Value 1.23Cr 1.07Cr 99.18L 91.42L 1.72Cr 118.44Cr 1.76Cr 12Cr 4.66Cr 58Cr 4.62Cr 4.52Cr 199.69Cr EV / Sales 2026 *
0.57x
EV / Sales 2027 * -49.3x
Free-Float
77.71%
Yield 2026 *
-
Yield 2027 * -
1 day+1.13%
1 week-12.76%
Current month+0.09%
1 month+7.94%
3 months-13.55%
6 months-27.90%
Current year-38.04%
1 week 5.6
Extreme 5.6
6.58
1 month 5.16
Extreme 5.1578
7.08
Current year 4.8
Extreme 4.8
10.49
1 year 4.8
Extreme 4.8
13.69
3 years 3.76
Extreme 3.76
46.8
5 years 3.76
Extreme 3.76
449.25
10 years 3.76
Extreme 3.76
937.75
Manager TitleAgeSince
Chief Executive Officer 64 05/02/2018
Director of Finance/CFO 60 01/06/2020
Chief Tech/Sci/R&D Officer 65 01/05/2018
Director TitleAgeSince
Director/Board Member 64 01/08/2018
Director/Board Member 74 01/08/2018
Chairman 64 -
Date Insider Type Main position Quantity % Market Cap.
25/06/26 Free

Director

5,860 0.1088%
25/06/26 Free

Director

5,860 0.1088%
25/06/26 Free

Director

5,860 0.1088%
Change 5-day change 1-year change 3-year change Capi.($)
+1.13%-12.76%-36.12%-78.21% 3.56Cr
-1.29%-3.11%-0.39%+4.92% 4.97TCr
+2.59%-1.90%+369.48%+588.95% 3.81TCr
-1.78%+4.41%+7.42%+57.60% 3.53TCr
-1.80%-0.49%+26.70%-6.57% 3.51TCr
+0.06%+1.56%+4.41%+27.42% 2.72TCr
+2.68%-1.60% - - 1.61TCr
-0.68%-0.79%+67.31%+115.88% 1.54TCr
+1.12%+1.91%+15.90%+19.65% 1.39TCr
-0.17%+1.37%+15.75%-30.62% 1.3TCr
Average +0.16%-2.02%+52.27%+77.67% 2.44TCr
Weighted average by Cap. -0.23%-0.65%+73.92%+118.02%

Financials

2026 *2027 *
Net sales 2.17Cr 1.89Cr 1.75Cr 1.61Cr 3.04Cr 208.75Cr 3.1Cr 21Cr 8.22Cr 102.24Cr 8.14Cr 7.96Cr 351.95Cr 50L 43.7L 40.32L 37.17L 70.05L 48Cr 71.6L 4.82Cr 1.9Cr 24Cr 1.88Cr 1.84Cr 81Cr
Net income -9.39Cr -8.2Cr -7.57Cr -6.98Cr -13Cr -903.83Cr -13Cr -90Cr -36Cr -442.66Cr -35Cr -34Cr -1.52TCr -12Cr -11Cr -10Cr -9.23Cr -17Cr -1.2TCr -18Cr -119.72Cr -47Cr -585.84Cr -47Cr -46Cr -2.02TCr
Net Debt -2.33Cr -2.03Cr -1.88Cr -1.73Cr -3.26Cr -224.22Cr -3.33Cr -22Cr -8.83Cr -109.81Cr -8.74Cr -8.55Cr -378.03Cr -28Cr -25Cr -23Cr -21Cr -40Cr -2.72TCr -40Cr -271.97Cr -106.97Cr -1.33TCr -105.97Cr -103.64Cr -4.58TCr
Logo Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Employees
82
Date Price Change Volume
17/26/17 $5.775 +0.43% 11,582
16/26/16 $5.750 -0.35% 54,756
15/26/15 $5.770 -5.49% 65,307
14/26/14 $6.105 -4.01% 1,02,514
13/26/13 $6.360 -3.93% 1,89,230
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.750USD
Average target price
56.29USD
Spread / Average Target
+878.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALGS Stock